On May 22, 2026 ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, reported new survey data highlighting the diverse treatment preferences and decision-making priorities of patients with Bacillus Calmette–Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC). The findings were presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2026, May 17–20, 2026, at the Pennsylvania Convention Center in Philadelphia, Pennsylvania.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The mixed-methods study, conducted in partnership with Fight Bladder Cancer, a UK-based patient advocacy organization, explored how patients with NMIBC who were currently receiving or had previously received BCG weigh radical cystectomy against bladder-sparing therapies following BCG treatment failure. The study provides a contemporary, patient-centered perspective on the factors influencing treatment decision-making in this setting.

"Treatment decisions for patients with BCG-unresponsive NMIBC are deeply personal and often complex," said Patrick Soon-Shiong, M.D., Founder, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio. "These findings reinforce the importance of incorporating patient perspectives, quality-of-life considerations, and individual treatment priorities into shared decision-making conversations."

The study used an online questionnaire completed by 86 UK adults living with NMIBC who were currently receiving or had previously been treated with BCG. This survey data was supplemented by one-on-one interviews and focus group discussions. Together, these methods were designed to evaluate treatment experiences, priorities, and trade-off preferences related to bladder-sparing approaches versus radical cystectomy following BCG failure.

The data showed that treatment preferences among UK patients with NMIBC are highly individualized, shaped by past treatment experiences, personal values, and age. Key findings include:

Patients actively receiving BCG were more likely to favor bladder preservation strategies
Patients who had previously undergone radical cystectomy were more likely to support repeating that decision
Older participants demonstrated a lower preference for radical cystectomy
Clinical effectiveness, including impact on recurrence, progression, and life expectancy, was identified as the most important factor influencing treatment decisions
Lifestyle disruption and quality-of-life considerations varied across patients, with male participants expressing greater concern regarding the daily-life impact of radical cystectomy
The authors concluded that UK adults living with NMIBC have widely varying treatment priorities—some placing greater weight on cancer control and life expectancy, while others prioritize quality of life and bladder preservation—with many willing to accept trade-offs, such as more frequent hospital visits, to avoid radical cystectomy. Taken together, the findings underscore that there is no one-size-fits-all approach to treatment decisions in this population, and highlight the importance of individualized, patient-centered care.

(Press release, ImmunityBio, MAY 22, 2026, View Source [SID1234666012])

On May 22, 2026 InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, reported that the abstracts of two clinical studies of the Company’s novel BCL2 inhibitor mesutoclax have been published on the official website of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper). The study of mesutoclax for the treatment of myeloid malignancies was selected for an oral presentation at this year’s ASCO (Free ASCO Whitepaper) annual meeting, and the research on mesutoclax for B-cell malignancies was chosen for a poster presentation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The following data has just been released on the ASCO (Free ASCO Whitepaper) official website, with updated oral presentation data to be announced on June 2 Central Time. The data show that mesutoclax demonstrates outstanding efficacy and safety in treating various hematologic malignancies.

Oral Presentation

Safety, tolerability, and efficacy of mesutoclax (ICP-248) in combination with azacitidine in patients with myeloid malignancies (Abstract No.: 6506)

The study enrolled patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Mesutoclax has demonstrated favorable safety and efficacy in the treatment of both MDS and AML.

Among evaluable treatment-naïve (TN) MDS patients, the overall response rate (ORR) per IWG 2006 criteria was 100%, including complete response (CR) in 20%, and marrow CR in 80%. The composite CR rate was 70% per IWG 2023 criteria including 30% CR even when most patients only received 1 cycle treatment.

Among the evaluable TN AML patients, 85.7% achieved composite CR (cCR, CR+CRi). Among those who achieved cCR, 86.7% were MRD (Minimal Residual Disease) negative per flow cytometry. cCR was 75% in adverse risk per 2017 ELN classification. The duration of response (DOR) rate at 3 months was 91.7%. The 6-month overall survival (OS) rate was 94.1%.

There were no dose-limiting toxicity (DLT) or tumor lysis syndrome (TLS) events in the study.

The updated research data, including findings from studies on relapsed or refractory (R/R) AML patients (including those with prior BCL2 inhibitor treatment failure), hematologic recovery, and data related to the TP53-mutated population, will be further disclosed following the oral presentation at the ASCO (Free ASCO Whitepaper) annual meeting.

Poster Presentation

Efficacy and safety of mesutoclax (ICP-248) in combination with orelabrutinib in patients with B-cell malignancies: A pooled analysis (Abstract No.: 7073)

The study enrolled patients with R/R mantle cell lymphoma (MCL), R/R marginal zone lymphoma (MZL), and TN chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The data demonstrated that mesutoclax combined with orelabrutinib exhibited favorable efficacy and safety in the treatment of these B-cell malignancies, suggesting that this all oral, chemo-free regimen has the potential to establish a novel therapeutic option for patients with B-cell non-Hodgkin lymphoma.

All treatment groups achieved an overall response rate (ORR) of 100% and a high complete response rate (CRR). Deep response was observed in patients receiving mesutoclax 125mg combined with orelabrutinib.

Among MCL and MZL patients who had at least one disease evaluation, the CRR was 100% and 50% respectively. 38.5% of patients achieved peripheral blood (PB) undetectable MRD (uMRD).

For TN CLL/SLL, 76.2% of patients had moderate or high TLS risk, and 14.3% had TP53 mutation or del (17p). In the CLL/SLL patients receiving mesutoclax 125 mg, the CRR was 38.1%, and the peripheral blood uMRD rate at 36-week was 65%. The 12-month progression-free survival (PFS) rate was 100%.

Mesutoclax in combination with orelabrutinib demonstrated a tolerable safety profile in all treatment groups. No treatment-related adverse events (TEAEs) leading to drug discontinuation or death reported. No clinical or laboratory TLS occurred.

Note:

1. IWG criteria refers to International Working Group (IWG) response criteria in myelodysplasia.

2. CRi refers to complete response with incomplete hematologic recovery.

(Press release, InnoCare Pharma, MAY 22, 2026, View Source [SID1234666028])

On May 22, 2026 ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, reported preliminary results from a new health economic analysis demonstrating that ANKTIVA (nogapendekin alfa inbakicept-pmln; NAI) plus Bacillus Calmette–Guérin (BCG) achieved a lower cost per sustained complete responder compared to TAR-200 in patients with BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ ± papillary disease (NMIBC CIS). The findings were presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2026, May 17–20, 2026, at the Pennsylvania Convention Center in Philadelphia, by Ruchika Talwar, M.D., Medical Director and Assistant Professor Urologic Oncology at Vanderbilt Health.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The authors developed a cost-consequence model comparing ANKTIVA plus BCG, using data from the QUILT-3.032 study, with TAR-200, using data from the SunRISe-1 trial, and evaluated both clinical and economic outcomes in a U.S. Medicare population. A multi-state Markov model incorporating key NMIBC health states and clinical outcomes derived from a matched-adjusted indirect comparison (MAIC) of the two trials was used to assess costs associated with treatment acquisition, administration, healthcare resource utilization, radical cystectomy, and mortality.

Key findings include:

Cost per cystectomy avoided: ANKTIVA plus BCG demonstrated savings of $109,622 at Year 1, $151,438 at Year 2, and $60,393 at Year 3 compared to TAR-200
Cost per cystectomy-free month: Savings of $9,370 at Year 1, $6,144 at Year 2, and $1,520 at Year 3
Cost per complete responder: Savings of $313,775 at Year 1 and $282,013 at Year 2
Cost reductions were primarily driven by lower drug acquisition and administration costs, based on complete response rates derived from an indirect treatment comparison—49.6% for ANKTIVA plus BCG versus 45.9% for TAR-200.

The authors concluded that ANKTIVA plus BCG offers direct cost savings across measurable clinical outcomes for patients with BCG-unresponsive NMIBC CIS compared to TAR-200 in a U.S. Medicare population, with savings persisting across all three years of the analysis.

"This health economic analysis reflects our dual mission of developing breakthrough immunotherapies that meaningfully extend lives, while ensuring these innovations are accessible within the broader healthcare landscape. By analyzing the rigorous economic efficiencies of our treatments, we are better positioned to ensure more patients can receive the most innovative and accessible cancer treatments available today," said Patrick Soon-Shiong, M.D., Founder, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio. "These results solidify the potential value of ANKTIVA plus BCG in delivering durable responses while reducing costs to the Medicare healthcare system."

"These findings reinforce the importance of aligning clinical innovation with both economic value and patient preferences," said Ruchika Talwar, M.D., Medical Director and Assistant Professor Urologic Oncology at Vanderbilt Health. "In BCG-unresponsive NMIBC, treatment decisions are not solely about response rates; they are about durability, quality of life, and ensuring patients have access to therapies that are both effective and sustainable within the healthcare system."

About BCG-Unresponsive NMIBC CIS

Non-muscle-invasive bladder cancer (NMIBC) represents approximately 75% of all bladder cancer diagnoses in the United States. Patients with carcinoma in situ (CIS) who become unresponsive to BCG therapy face a high risk of recurrence and progression and often have limited bladder-sparing treatment options available.

About ANKTIVA (nogapendekin alfa inbakicept-pmln)

The interleukin-15 (IL-15) cytokine plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved in killing cancer cells. By activating NK cells, ANKTIVA overcomes the tumor escape phase of clones resistant to T cells and restores memory T cell activity with resultant prolonged duration of complete response. ANKTIVA is a first-in-class IL-15 receptor agonist IgG1 fusion complex, consisting of an IL-15 mutant (IL-15N72D) fused with an IL-15 receptor alpha, which binds with high affinity to IL-15 receptors on NK, CD4+, and CD8+ T cells. This fusion complex of ANKTIVA mimics the natural biological properties of the membrane-bound IL-15 receptor alpha, delivering IL-15 by dendritic cells and driving the activation and proliferation of NK cells with the generation of memory killer T cells that have retained immune memory against these tumor clones.

IMPORTANT SAFETY INFORMATION

INDICATION AND USAGE: ANKTIVA is an interleukin-15 (IL-15) receptor agonist indicated with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.

WARNINGS AND PRECAUTIONS: Risk of Metastatic Bladder Cancer with Delayed Cystectomy. Delaying cystectomy can lead to the development of muscle-invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after a second induction course of ANKTIVA with BCG, reconsider cystectomy.

DOSAGE AND ADMINISTRATION: For Intravesical Use Only. Do not administer by subcutaneous or intravenous routes.

Please see the complete Indication and Important Safety Information and Prescribing Information for ANKTIVA at Anktiva.com.

(Press release, ImmunityBio, MAY 22, 2026, View Source [SID1234666013])

On May 22, 2026 BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, reported positive clinical data from three clinical data poster presentations and three publication-only abstracts at the 2026 ASCO (Free ASCO Whitepaper) Annual Meeting, taking place May 29–June 2, 2026 at McCormick Place, Chicago, Illinois. The presentations will include two poster presentations featuring data from BriaCell’s ongoing pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor, Bria-ABC (ClinicalTrials.gov identifier: NCT06072612), and one poster highlighting further analyses of Phase 2 data.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"These data from the ongoing pivotal Phase 3 Bria-ABC study highlight Bria-IMT’s potential to preserve quality of life, limit toxicity, and potentially support self-administration — benefits that would be clinically meaningful for patients," stated Adam M. Brufsky, MD, PhD, FACP, Professor of Medicine at the University of Pittsburgh School of Medicine and Medical Director of the Magee-Women’s Cancer Program.

"The Phase 2 study of the combination of a whole-cell vaccine with anti-PD-1 demonstrated a tolerable safety profile and the emergence of a long-term survivor cohort inclusive of the heavily pre-treated nature of these patients," stated Saranya Chumsri, M.D., principal investigator in the Phase 3 study of Bria-IMT+CPI, and Professor of Oncology at Mayo Clinic Florida. "I’m proud to do this work that brings new attention to metastatic breast cancer patients who have few or no remaining treatment options."

"Our positive clinical data across six presentations or abstracts at the ASCO (Free ASCO Whitepaper) 2026 Annual Meeting highlight the progress we are making in our clinical programs," noted William V. Williams, MD, BriaCell’s President & CEO. "These data reflect our commitment to advancing innovative therapeutic options for patients with cancer patients who need better treatments."

The details of the presentations and publish-only abstracts are listed below.

Abstract Title: Survival with Bria-IMT + CPI in advanced metastatic breast cancer at 12 and 24 months.
Session Type/Title: Poster Session – Breast Cancer—Metastatic
Poster Board: 222
Date and Time: June 1, 2026, 1:30 PM-4:30 PM CDT
Clinical Data: 32 Phase 2 Bria-IMT patients were randomized to receive immune checkpoint inhibitor (CPI) in the first cycle or delayed to the second cycle. Two Bria-IMT formulations were also evaluated. Patients had median age of 61 (range 41-80) and had received median 6 prior therapies (range 2-13). Median overall survival (OS) was 13.3 vs. 7.4 months for starting CPI in cycle 1 versus cycle 2. In patients who developed an immune response as measured by delayed-type hypersensitivity (DTH) positive vs. negative, OS was 11.9 vs. 4.7 months, with 48% 12-months survival vs 0.0% 12-month survival. Patients with circulating tumor cells (CTCs) <5 vs. > 5 at baseline had median OS of 16.6 vs. 5.5 months. Median OS was 16.6 months for the formulation selected for the Phase 3 study with 52% of patients surviving at 12-months. The 12-month survival rate was 44% and the 24-month rate was 26%. There were no treatment-related discontinuations and no unexpected safety signals.

Conclusions: In heavily pretreated MBC patients, Bria-IMT demonstrated a tolerable safety profile and the emergence of a long-term survivor cohort. Durable survival rates were observed beyond 12 and 24 months. Differential survival favored the Phase 3 formulation, DTH positivity, lower baseline circulating tumor cell (CTC) levels, and early CPI sequencing. These findings support prospective validation of DTH and CTC as predictive biomarkers for effectiveness of the Bria-IMT regimen and the continued use of the Phase 3formulation in the ongoing Phase 3 study Bria-ABC.

Abstract Title: Quality of life and treatment tolerability of Bria-IMT + CPI in metastatic breast cancer.
Session Type/Title: Poster Session – Breast Cancer—Metastatic
Poster Board: 221
Date and Time: June 1, 2026, 1:30 PM-4:30 PM CDT
Summary: Heavily pretreated MBC patients in the pivotal Bria-ABC demonstrated stable global health and key functional domains. Measurements included quality of life (QOL) and time without symptoms or toxicity (TWiST). Blinded data indicated that QOL was largely preserved in a heavily pretreated population with prior antibody-drug conjugate (ADC), check point inhibitor (CPI), and cyclin-dependent kinase 4/6 (CDK4/6) inhibitor exposure. Clinical data demonstrates meaningful benefits without significant toxicity. Ongoing follow up will further characterize durability of patient-reported outcomes and clinical correlation. Data further supports decentralized care and potential home self-administration of the Bria-IMT+CPI regimen.

Abstract Title: Monitoring blood-based biomarkers as early predictors of progression-free survival in a randomized Bria-ABC Phase 3 trial for advanced metastatic breast cancer: An ongoing analysis.
Session Type/Title: Poster Session – Developmental Therapeutics—Immunotherapy
Poster Board: 442
Date and Time: May 30, 2026, 1:30 PM-4:30 PM CDT
Summary: In an ongoing analysis of heavily treated MBC patients, we observed that in the entire blinded population, 65% of patients had stability/drop in Cancer-Associated Macrophage-Like cells (CAMLs) and this significantly correlated with better progression free survival (PFS). Treatment arm specific comparisons will not be unblinded until completion of the designated milestone (144 mortalities).

Publication-Only Abstract Title: Cell-based second-generation immunotherapy BC1 in metastatic breast cancer.
Summary: Dose escalation from 20M to 60M and combination with CPI showed tolerable intradermal BC1, Bria-OTS, and potential clinical benefit in refractory MBC patients. One patient received 17 cycles with 12 months of disease control. Expansion cohorts will assess HLA match, DTH, dose optimization, and combination activity. Based on very early preliminary data, BC1, Bria-OTS first generation, is a potential new option for late-stage cancer patients with minimal toxicity and potential home administration as a single agent. Clinical trial information: NCT06471673.

Publication-Only Abstract Title: Liquid biopsy to stratify metastatic breast cancer progression risk using multi-analyte cell subtyping prior to systemic therapy.
Summary: Circulating tumor cells were uncommon in metastatic breast cancer patients but correlated with very poor clinical outcomes. In parallel analysis, CAMLs were common with CAML size correlating with increasingly poorer outcomes. By combining CTC & CAML subtypes, MBC patients were more accurately stratified by risk of progression and death. Additional multivariate studies correlating treatment class and tumor response rates are ongoing.

Publication-Only Abstract Title: Monitoring PD-L1 expression in circulating cancer associated cells for prediction of clinical outcomes in metastatic breast cancer patients treated with immune checkpoint inhibitors.
Summary: In this study of MBC patients treated with programmed death-ligand 1 (PD-L1) immune checkpoint inhibitors (ICIs), tissue combined positive score (for PD-L1) did not correlate with PD-L1 expression in CTCs or tumor-macrophage fusion cells. Further, neither Combined Positive Score (CPS) nor baseline PD-L1 in CTC/ tumor-macrophage fusion cells (TMFCs) predicted clinical outcomes in ICI therapies. However, PD-L1 in CTC/TMFCs~40 days post-induction of ICI did predict better response rates. While this study suggests predictive value of monitoring PD-L1 in blood during ICI therapies, further studies are required to refine and validate these findings.

Following the presentation, copies of the posters will be made available at View Source

(Press release, BriaCell Therapeutics, MAY 22, 2026, View Source [SID1234666029])

On May 22, 2026 Oxford Vacmedix (OVM), the UK biotech company developing novel immunotherapies to treat cancer reported that the Phase 1b dose expansion part of the Phase 1 trial of OVM-200 will be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) in Chicago at the end of May. The poster presentation will be part of the session on Developmental Therapeutics – Immunotherapy. This follows the publication of Phase 1a, which established dosing, in a Lancet group journal earlier this year.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This Phase 1 clinical trial of OVM-200 is a multicentre, open-label, first-in-human evaluation of OVM-200, an immunotherapy developed using Oxford Vacmedix’s Recombinant Overlapping Peptide (ROP) therapeutic platform. 36 patients with advanced NSCLC (non-small cell lung cancer) ovarian cancer, or prostate cancer and with no HLA restrictions, were treated in the trial. The results show:

Excellent Safety Profile (primary endpoint): OVM-200 is very well tolerated with no serious adverse drug reactions or no dose-limiting toxicities. The only adverse effects were Grade 1 injection-site reactions.
Very strong Immunogenicity (secondary endpoint): the immune responses for both antibodies and for T cells were very strong even in an advanced Stage IV patient population.
Therapeutic Dose established (secondary endpoint) based on the immune response, the 2mg dose selected in Phase 1a was chosen for expanded immunisations of up to 11 doses of 2mg in Phase 1b.
Early observations of clinical efficacy with stable disease in NSCLC and PSA responses in prostate cancer following progression to other therapies.
Professor Martin Forster, Chief Investigator at University College Hospital, London, said:

We are very impressed with the results of this Phase 1 trial for OVM-200. In particular, seeing six months stable disease in a Stage IV lung cancer patient is a very promising result, for follow up. We look forward to further development with Phase 2 trials of OVM-200.

William Finch, Chief Executive Officer of Oxford Vacmedix, said:

The completion of this clinical trial of OVM-200 marks an important milestone for the company. We are of course very grateful for the participation of the patients and the dedication of the staff in the clinics in this first trial of OVM-200. We are already in discussions about investment to fund Phase 2 development.

(Press release, Oxford Vacmedix, MAY 22, 2026, View Source;utm_medium=rss&utm_campaign=ovm-200-phase-1-clinical-trial-accepted-for-presentation-at-asco [SID1234666014])